Pharmaceutical company reduces the price of cannabidiol by 40% in Brazilian pharmacies

The Ease Labs, a Brazilian industry specialized in cannabis products, announced that its entire line of isolated cannabidiol had a 40% price reduction starting on July 21. 

With a concentration of 100 mg/mL and available in 10 mL and 30 mL presentations, the products experienced a drop in prices at pharmacies throughout Brazil. The 30 ml bottle, previously priced at R$ 1,142, now costs R$ 685.20. The 10 ml bottle, previously priced at R$ 409, is now priced at R$ 245 with a 40% discount.

"The measure is a concrete step to increase access. This way, we can truly generate a transformation in the Brazilian health market and in people's lives," said Ease Labs' co-CEO, Gustavo Palhares.

Growth of the medical cannabis market

The market for products derived from cannabis sativa has been experiencing strong expansion. According to data from the consulting firm Close-Up, in April of this year, the segment was the fastest-growing among potential psychotropic markets, moving R$ 237.9 million — a 41.2% increase compared to the same period in 2024. 

Cannabidiol accounted for 52% of this volume, with a 31.1% increase, while extracts represented 48%, showing a growth of 63.8%.

According to a survey by Kaya Mind, the number of patients using medical cannabis grew by 56% between 2023 and 2024, reaching approximately 672,000 people. Despite the progress, the price of cannabidiol is still cited as one of the main obstacles to adherence and continuity of treatment.

In the March 2025 ranking by Close-Up, the cannabidiol market was led by Prati-Donaduzzi, Greencare, and Hypera Pharma, followed by Ease Labs and Biolab Corp. Among the main companies, Ease Labs recorded the second-highest growth rate in the period, with an increase of 191.1%.

Movement as a trend

For Ease Labs, vertically integrated production models, where companies control everything from plant cultivation to manufacturing and distribution, contribute to price reductions and can be adopted by the market. 

In early July, Prati-Donaduzzi had already announced cuts of up to 40% in three cannabidiol concentrations, reinforcing the trend of making treatment more accessible in Brazil.